These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 6326063)

  • 1. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Sinkule JA
    Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
    Vogelzang NJ; Raghavan D; Kennedy BJ
    Am J Med; 1982 Jan; 72(1):136-44. PubMed ID: 6277188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podophyllotoxin derivative VP 16-213.
    Arnold AM
    Cancer Chemother Pharmacol; 1979; 3(2):71-80. PubMed ID: 389478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of refractory germ cell cancer with Etoposide.
    Lederman GS; Garnick MB; Canellos GP; Richie JP
    J Clin Oncol; 1983 Nov; 1(11):706-9. PubMed ID: 6321675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 7. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
    Schmoll HJ; Niederle N; Achterrath W
    Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide (VP-16-213).
    Issell BF; Crooke ST
    Cancer Treat Rev; 1979 Jun; 6(2):107-24. PubMed ID: 385138
    [No Abstract]   [Full Text] [Related]  

  • 9. Etoposide in leukemia, lymphoma and bone marrow transplantation.
    Stadtmauer EA; Cassileth PA; Gale RP
    Leuk Res; 1989; 13(8):639-50. PubMed ID: 2677526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide (VP-16-213). Current status of an active anticancer drug.
    O'Dwyer PJ; Leyland-Jones B; Alonso MT; Marsoni S; Wittes RE
    N Engl J Med; 1985 Mar; 312(11):692-700. PubMed ID: 2983208
    [No Abstract]   [Full Text] [Related]  

  • 12. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
    Cersosimo RJ; Hong WK
    J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I clinical study of NK 171 (etoposide)].
    Kimura K; Yamada K; Niitani H
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic daily administration of oral etoposide.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):71-4. PubMed ID: 2154861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of VP-16-213 in non-small-cell lung cancer.
    Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
    Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide: current status and future perspectives in the management of malignant neoplasms.
    Belani CP; Doyle LA; Aisner J
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S118-26. PubMed ID: 8070020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
    Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
    Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.